Skip to main content

Thermo Fisher Scientific Extends Tender Offer for Dionex

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Thermo Fisher Scientific today announced it has extended its $2.1 billion offer to purchase Dionex.

Its offer to acquire all outstanding shares of the chromatography firm at $118.50 per share is now set to expire at midnight EDT Feb. 17. All other terms of the deal remain, the company said, adding the acquisition is anticipated to be completed later this quarter.

Thermo Fisher announced its plan to purchase Dionex last month. Earlier this week, Thermo Fisher said that the deal had cleared the pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

As of 5 p.m. on Thursday, approximately 3,466,729 shares of Dionex common stock, or a little less than 20 percent of all outstanding shares, had been tendered into and not withdrawn from the offer, Thermo Fisher said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.